Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 09 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

This partnership marks Zydus' entry into the North American biosimilar market, aiming to enhance access to affordable oncology care. The press release emphasizes the collaboration's potential to drive growth and improve patient access to immunotherapy treatments.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 09, 2025, titled "Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases